e-drug
[Top] [All Lists]

[e-drug] New Phase in WHO's External QC Lab Scheme

E-DRUG: New Phase in WHO's Quality Control Laboratory Scheme
-----------------------------------------------------------------------------------------------

Quality of medicines is a major public health challenge, particularly in light 
of the cross-border health-related issues and the international dimensions of 
trade. Quality assurance is a wide-ranging concept that helps to ensure that 
quality medicines reach the patient; it covers all matters that individually or 
collectively influence the quality of a product. Quality control has 
traditionally been one of the key elements in quality assurance and therefore 
pharmaceutical quality control laboratories play a major role in protecting 
patients.

Quality control (QC) testing is complex, and errors are costly and may 
jeopardize patient safety. Patients may receive ineffective or even harmful 
medicines; if genuine quality deficiencies are not identified, conversely, if 
non-conforming results are falsely interpreted as quality failures, expensive 
medicines may be returned or destroyed, potentially leaving patients without 
life-saving treatment until the products are replaced at sometimes enormous 
additional cost. Given these high stakes, trust in a QC laboratory's 
capabilities is essential for all stakeholders who request its services.

WHO is pleased to announce Phase 6 of its External Quality Assurance Assessment 
Scheme (EQAAS) at preferential fees far below cost for participants from lower- 
and middle-income countries. In order to enhance the efficiency and save costs, 
for each shipment two studies will be carried out. Fees are based on the World 
Bank classification of income. The cost per shipment for two studies is as 
follows:

- Laboratories from low-income countries:  US$ 1000
- Laboratories from middle-income countries: US$ 2000
- Laboratories from high-income countries:  US$ 4000
The fee covers shipment of the two test samples together with the study 
protocols and the subsequent statistical evaluation of the submitted results. 
WHO informs the laboratories about their performance and provides additional 
guidance for improving their capabilities. The scheme is set out in close 
cooperation with related WHO programmes, including the programme dealing with 
the prequalification of QC laboratories.

International donors may be approached for funding of participation in the 
EQAAS. The Global Fund to Fight AIDS, Tuberculosis and Malaria encourages grant 
applicants to include this item in their applications for funding. The Global 
Fund requires grant recipients to arrange for systematic random QC testing of 
products throughout the in-country supply chain for medicines worth 
approximately USD 600 million delivered to grant-funded programmes every year.  
It also funds large quantities of laboratory equipment and reagents. Other 
donors have similar policies.

WHO invites laboratories to participate in EQAAS Phase 6 studies. To ensure 
continued assistance to laboratories in Member States, WHO will offer advice on 
possible funding sources through WHO country projects for laboratories in 
developing countries that have no means to recuperate the fee, and for whom the 
fee presents an obstacle for participation.

WHO at present offers the only global, independent scheme to measure 
laboratories' QC testing capabilities.  The EQAAS was established by WHO in 
2000 at the request of the Global Fund as a mechanism to maximize health 
benefits achieved on grant investments in pharmaceuticals and laboratory 
supplies.  The EQAAS has proven to be a major asset to WHO Member States. More 
than 60 laboratories across WHO's six regions, many of them in Africa, have 
participated in the past comparative external assessment studies. Participation 
in such studies  is mandatory according to WHO's good practices for 
pharmaceutical quality control laboratories  and for ISO 17025 accreditation.

For more information and expression of interest to participate in this new 
phase in WHO's QC laboratory  scheme, please contact WHO at the following 
email:  EQAAS@who.int .
________________________________
Dr Sabine Kopp
Group Lead, Medicines Quality Assurance
Technologies Standards and Norms
Regulation of Medicines and Other Health Technologies
<http://www.rijksoverheid.nl/ministeries/vws> 
World Health Organization
"KOPP, Sabine" <kopps@who.int>

<Prev in Thread] Current Thread [Next in Thread>
  • [e-drug] New Phase in WHO's External QC Lab Scheme, KOPP, Sabine <=